Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[A preliminary study on the outcome of lower-risk myelodysplastic syndrome by low-dose decitabine].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi - 14 Apr 2017

Ye L, Ren Y L, Xie L L, Luo Y W, Lin P P, Zhou X P, Ma L Y, Mei C, Xu W L, Wei J Y, Jiang H F, Zhang L M, Zeng H, Tong H Y

Abstract excerpt

Objective: To assess the efficiency and safety of low-dose decitabine in patients with lower-risk myelodysplastic syndrome (MDS) to couple with the clinical significance of MDS-related gene mutations. Methods: This study was done in 4 institutions in Zhejiang Province. A total of 62 newly diagnosed patients with lower-risk MDS were assigned to two groups of decitabine (12 mg·m(-2)·d(-1) for 5 consecutive days)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Azacitidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Decitabine

Share to Disease-Free Survival

Share to Myelodysplastic Syndromes

Share to Prognosis

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 28468092
DOI: 10.3760/cma.j.issn.0253-2727.2017.04.009
PMCID: PMC7342717

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[A preliminary study on the outcome of lower-risk myelodysplastic syndrome by low-dose decitabine].PMID 28468092Read ↗

[Clinical features of SF3B1 mutation in patients with myelodysplastic syndrome with excess blasts].Semantic proximity Read ↗

Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone.Semantic proximity Read ↗

Therapy for lower-risk MDS.Semantic proximity Read ↗

[Predict response to decitabine in patients with myelodysplastic syndrome and related neoplasms].Semantic proximity Read ↗

[Characteristics and Clinical Significance of Gene Mutation in Patients with Myelodysplastic Syndrome].Semantic proximity Read ↗

Decitabine in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial.Semantic proximity Read ↗

ASXL1 Mutations with Serum EPO Levels Predict a Poor Response to Darbepoetin Alfa in Lower-Risk MDS: W-JHS MDS01 TrialSemantic proximity Read ↗

Elevated serum direct bilirubin is predictive of a poor prognosis for primary myelodysplastic syndrome.Semantic proximity Read ↗

Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study.Semantic proximity Read ↗

Decitabine induces change of biological traits in myelodysplastic syndromes via FOXO1 activationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.